[ad_1]
MindMed Inc. said Tuesday it’s on track to launch Phase 3 clinical trials with up to 440 people starting later this year for its treatment of generalized anxiety disorder (GAD) through use of lysergide D-tartrate (LSD) in a clinical setting.
[ad_2]
Source link
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...
Investors will measure the response to this week's selloff, which came at a time when markets are entering a strong...
Tesla CEO and X owner Elon Musk gestures behind protective glass during a rally for Republican presidential nominee and former...
Sam Altman Co-founder and CEO of OpenAI speaks during the Italian Tech Week 2024 at OGR Officine Grandi Riparazioni on...
A lone traveler makes his way past a nearly deserted TSA security screening area at Orlando International Airport ahead of...
© AlertsPicks.com
